Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2008

01.01.2008 | Lab. Investigation-Human/Animal Tissue

Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells

verfasst von: Yuan Zhang, Cheng-wei Wang, Zhi-gang Wang, Dao-xin Ma, Shun Pan, Shu-gan Zhu, Feng Li, Bo Wang

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

The multiple drug resistance protein (MDR1) is frequently overexpressed in human glioma. The aim of this study is to clone the MDR1 promoter from C6/ADR, construct the double suicide genes expressive vector controlled by MDR1 promoter, and explore its targeted expression in C6/ADR cells. MDR1 promoter from C6/ADR genomic DNA, which was linked with T vector, was amplified by using Polymerase chain reaction (PCR). After cut by NdeI and HindIII, MDR1 promoter was cloned into pcDNA3-TK (thymidine kinase) plasmid. The cytosine deaminase (CD) gene from pcDNA3-CD-TK plasmid was directly cloned into the above vector to construct pcDNA3-MDR1-promoter-CD-TK vector. Then this vector was transfected into C6 and C6/ADR cells respectively by liposome. After selection by G418, the tumor cell lines were stably established. Then these cell lines were examined through PCR and RT-PCR to respectively detect the integration and expression of TK and CD genes. The results showed the length and sequence of MDR1 promoter amplified by PCR were confirmed by DNA sequencing. The pcDNA3-MDR1-promoter-CD-TK expression vectors were constructed successfully. PCR indicated the double suicide genes were integrated into C6 and C6/ADR cells. RT-PCR reveled that CD and TK genes expressed in C6/ADR/CD-TK cells, whereas not in C6/CD-TK cells. In conclusions, construction of expressive vector containing double suicide genes controlled by MDR1 promoter with targeted expression in C6/ADR will provide a sound basis for targeted gene therapy for multidrug resistance (MDR) glioma.
Literatur
1.
Zurück zum Zitat Hau P, Fabel K, Baumqart U et al (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100:1199–1207PubMedCrossRef Hau P, Fabel K, Baumqart U et al (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100:1199–1207PubMedCrossRef
2.
Zurück zum Zitat Comerford KM, Wallace TJ, Karhausen J et al (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387–3394PubMed Comerford KM, Wallace TJ, Karhausen J et al (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387–3394PubMed
3.
Zurück zum Zitat Montaudon D, Benchekroun MN, Londos-Gagliardi et al (1990) Chromosomal modification of a rat glioblastoma cell line during the acquisition and reversal of doxorubicin resistance. Anticancer Res 10:1667–1676PubMed Montaudon D, Benchekroun MN, Londos-Gagliardi et al (1990) Chromosomal modification of a rat glioblastoma cell line during the acquisition and reversal of doxorubicin resistance. Anticancer Res 10:1667–1676PubMed
4.
Zurück zum Zitat Ogretmen B, Ahmad R (1999) Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-II B/p65 and c-Fos. Transcription factors and their interaction with the CAAT region. Biochemistry 38:2189–2199PubMedCrossRef Ogretmen B, Ahmad R (1999) Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-II B/p65 and c-Fos. Transcription factors and their interaction with the CAAT region. Biochemistry 38:2189–2199PubMedCrossRef
5.
Zurück zum Zitat Kartner N, Evernden-Porelle D, Bradley G et al (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820–823PubMedCrossRef Kartner N, Evernden-Porelle D, Bradley G et al (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820–823PubMedCrossRef
6.
Zurück zum Zitat Choi KH, Chen CJ, Krieqler M et al (1988) An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the MDR1 (P-glycoprotein) gene. Cell 53:519–529PubMedCrossRef Choi KH, Chen CJ, Krieqler M et al (1988) An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the MDR1 (P-glycoprotein) gene. Cell 53:519–529PubMedCrossRef
7.
Zurück zum Zitat Fairchild CR, Moscow JA, O’Brien EE et al (1990) Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. Mol Pharmacol 37:801–809PubMed Fairchild CR, Moscow JA, O’Brien EE et al (1990) Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. Mol Pharmacol 37:801–809PubMed
8.
Zurück zum Zitat Bell DR, Gerlach JH, Kartner N et al (1985) Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 3:311–315PubMed Bell DR, Gerlach JH, Kartner N et al (1985) Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 3:311–315PubMed
9.
Zurück zum Zitat Bourhis J, Goldstein LJ, Riou G et al (1989) Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 49:5062–5065PubMed Bourhis J, Goldstein LJ, Riou G et al (1989) Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 49:5062–5065PubMed
10.
Zurück zum Zitat Fojo A, Shen D, Mickley L et al (1987) Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 5:1922–1927PubMed Fojo A, Shen D, Mickley L et al (1987) Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 5:1922–1927PubMed
11.
Zurück zum Zitat Gerlach J, Bell D, Karakousis C et al (1987) P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 5:1452–1460PubMed Gerlach J, Bell D, Karakousis C et al (1987) P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 5:1452–1460PubMed
12.
Zurück zum Zitat Fojo A, Ueda K, Slamon D et al (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265–269PubMedCrossRef Fojo A, Ueda K, Slamon D et al (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265–269PubMedCrossRef
13.
Zurück zum Zitat Hui-zhu G, Gui-zhen Z, Ji-sheng Z et al (2005) Reversal of MDR1 gene-dependent multidrug resistance using short hairp in RNA expression vectors. Chin Med J 11:893–902 Hui-zhu G, Gui-zhen Z, Ji-sheng Z et al (2005) Reversal of MDR1 gene-dependent multidrug resistance using short hairp in RNA expression vectors. Chin Med J 11:893–902
14.
Zurück zum Zitat Madden MJ, Morrow CS, Nakagawa M et al (1993) Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem 268:8290–8297PubMed Madden MJ, Morrow CS, Nakagawa M et al (1993) Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem 268:8290–8297PubMed
15.
Zurück zum Zitat Sundseth R, Macdonald G, Ting J et al (1997) DNA elements recognizing NF-Y Sp1 regulate the human multidrug-resistance gene promoter. Mol Pharmacol 51:963–971PubMed Sundseth R, Macdonald G, Ting J et al (1997) DNA elements recognizing NF-Y Sp1 regulate the human multidrug-resistance gene promoter. Mol Pharmacol 51:963–971PubMed
16.
Zurück zum Zitat Ohga T, Uchium T, Makino Y et al (1998) Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance1 gene. J Biol Chem 273:5997–6000PubMedCrossRef Ohga T, Uchium T, Makino Y et al (1998) Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance1 gene. J Biol Chem 273:5997–6000PubMedCrossRef
17.
Zurück zum Zitat Liu F-S, Zhang Q-L, Zhao L et al (2001) Establishment of a multidrug C6/adr cell line and its characterization. Chin J Neurosurg 17:109–112 Liu F-S, Zhang Q-L, Zhao L et al (2001) Establishment of a multidrug C6/adr cell line and its characterization. Chin J Neurosurg 17:109–112
18.
Zurück zum Zitat Abbadessa V, Tolomeo M, Luparello M et al (1992) Selection of a new multidrug resistance cell line from friend leukemia cells by short and cyclic exposures to high concentrations of daunorubicin. Haematologia 77:137–141 Abbadessa V, Tolomeo M, Luparello M et al (1992) Selection of a new multidrug resistance cell line from friend leukemia cells by short and cyclic exposures to high concentrations of daunorubicin. Haematologia 77:137–141
19.
Zurück zum Zitat Fu-Sheng L, Zhong-cheng W, Qing-lin Z et al (2002) Establishment of multidrug-resistance cell line C6/adr and reversal of drug-resistance. Chin Med J 115:238–241 Fu-Sheng L, Zhong-cheng W, Qing-lin Z et al (2002) Establishment of multidrug-resistance cell line C6/adr and reversal of drug-resistance. Chin Med J 115:238–241
20.
Zurück zum Zitat Daniel P, Juraj H, Matthias R (2007) Suicide genes for cancer therapy. Mol Aspects Med 28:4–41CrossRef Daniel P, Juraj H, Matthias R (2007) Suicide genes for cancer therapy. Mol Aspects Med 28:4–41CrossRef
21.
Zurück zum Zitat Morokoff AP, Novak U (2004) Targeted therapy for malignant gliomas. J Clin Neurosci 11:807–818PubMedCrossRef Morokoff AP, Novak U (2004) Targeted therapy for malignant gliomas. J Clin Neurosci 11:807–818PubMedCrossRef
22.
Zurück zum Zitat Nakaya H, Ishizu A, Ikeda H et al (2003) In vitro model of suicide gene therapy for alpha-fetoprotein-producing gastric cancer. Anticancer Res 23:3795–3800PubMed Nakaya H, Ishizu A, Ikeda H et al (2003) In vitro model of suicide gene therapy for alpha-fetoprotein-producing gastric cancer. Anticancer Res 23:3795–3800PubMed
23.
Zurück zum Zitat Shen LZ, Wu WX, Xu DH et al (2002) Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene. World J Gastroenterol 8:270–275PubMed Shen LZ, Wu WX, Xu DH et al (2002) Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene. World J Gastroenterol 8:270–275PubMed
24.
Zurück zum Zitat Majumdar AS, Hughes DE, Lichtsteiner SP et al (2001) The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8:568–578PubMedCrossRef Majumdar AS, Hughes DE, Lichtsteiner SP et al (2001) The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8:568–578PubMedCrossRef
25.
Zurück zum Zitat Nooter K, Sonneveld P (1994) Clinical relevance of P-glycoprotein expression in haematological malignancies. Leu Res 18:233–243CrossRef Nooter K, Sonneveld P (1994) Clinical relevance of P-glycoprotein expression in haematological malignancies. Leu Res 18:233–243CrossRef
26.
Zurück zum Zitat Stavrovskaya AA (2000) Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 65:95–106 Stavrovskaya AA (2000) Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 65:95–106
27.
Zurück zum Zitat Chan H, Thorner P, Haddad G et al (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689PubMed Chan H, Thorner P, Haddad G et al (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689PubMed
28.
Zurück zum Zitat Niehans GA, Jaszcz W, Brunetto V et al (1992) Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 52:3768PubMed Niehans GA, Jaszcz W, Brunetto V et al (1992) Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 52:3768PubMed
29.
Zurück zum Zitat Epstein J, Xiao HQ, Oba BK (1989) P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 74:913PubMed Epstein J, Xiao HQ, Oba BK (1989) P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 74:913PubMed
30.
Zurück zum Zitat Ogretmen B, Ahmad R (2000) Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. Biochemistry 39:194–204PubMedCrossRef Ogretmen B, Ahmad R (2000) Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. Biochemistry 39:194–204PubMedCrossRef
31.
Zurück zum Zitat Walther W, Arlt F, Fichtner I et al (2007) Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression. Mol Cancer Ther 6:236–243PubMedCrossRef Walther W, Arlt F, Fichtner I et al (2007) Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression. Mol Cancer Ther 6:236–243PubMedCrossRef
32.
Zurück zum Zitat Sampath J, Sun D, Kidd VJ (2001) Mutant p53 cooperateswith ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276:39359–39367PubMedCrossRef Sampath J, Sun D, Kidd VJ (2001) Mutant p53 cooperateswith ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276:39359–39367PubMedCrossRef
Metadaten
Titel
Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells
verfasst von
Yuan Zhang
Cheng-wei Wang
Zhi-gang Wang
Dao-xin Ma
Shun Pan
Shu-gan Zhu
Feng Li
Bo Wang
Publikationsdatum
01.01.2008
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2008
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-007-9431-2

Weitere Artikel der Ausgabe 1/2008

Journal of Neuro-Oncology 1/2008 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.